Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

240
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
240

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Linerixibat: First Approval.

Drugs·2026
Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026
Same author

Guselkumab: Pediatric First Approval.

Paediatric drugs·2026
Same author

Taletrectinib: First Approval.

Drugs·2025
Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025
Same author

Correction: Mirdametinib: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.7K

Trastuzumab Rezetecan: First Approval.

Sheridan M Hoy1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|October 25, 2025
PubMed
Summary
This summary is machine-generated.

Trastuzumab rezetecan, an antibody-drug conjugate targeting HER2, has gained approval in China for advanced non-small cell lung cancer. This marks a significant milestone for the treatment of HER2-mutated lung cancer.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.6K

Related Experiment Videos

Last Updated: Jan 14, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.6K

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Trastuzumab rezetecan is an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2).
  • It is developed for various solid tumors, including breast, colorectal, gastric, gastroesophageal junction adenocarcinoma, and lung cancer.
  • Jiangsu HengRui Medicine Co., Ltd. is the developer of this therapeutic agent.

Purpose of the Study:

  • To summarize the developmental milestones of trastuzumab rezetecan.
  • To highlight the drug's first regulatory approval.
  • To document the journey leading to the approval for non-small cell lung cancer treatment.

Main Methods:

  • Review of developmental data and regulatory submissions.
  • Analysis of clinical trial outcomes (implied).
  • Summary of the drug's mechanism of action as an antibody-drug conjugate.

Main Results:

  • Trastuzumab rezetecan received approval from China's National Medical Products Administration in May 2025.
  • The approval is for adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC).
  • Patients must have HER2 (ERBB2)-activating mutations and have received at least one prior systemic treatment.

Conclusions:

  • The approval represents a significant advancement in targeted therapy for NSCLC.
  • Trastuzumab rezetecan offers a new treatment option for a specific subset of lung cancer patients.
  • This milestone signifies the successful development and regulatory validation of the drug.